Phaseline

Targets › TRPM2

TRPM2 (Transient receptor potential cation channel subfamily M member 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Dec 2028.

[Isoform 1]: Nonselective, voltage-independent cation channel that mediates Na(+) and Ca(2+) influx, leading to increased cytoplasmic Ca(2+) levels. Functions as a ligand-gated ion channel, gated by intracellular adenosine diphosphate ribose (ADP-ribose), Ca(2+), warm temperature, and oxidative stress. (UniProt, O94759)

Open in Phaseline: the race on TRPM2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
European Organisation for Research and Treatment of Cancer - EORTCRa223
alpha-emitting radium-223 dichloride targeting bone metastases
TRPM2Phase 3Prostate CancerDec 2028

Conditions

Prostate Cancer (1)

Modalities

small molecule (1)

Companies

European Organisation for Research and Treatment of Cancer - EORTC (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.